Zacks: Analysts Anticipate Pacira BioSciences, Inc. (NASDAQ:PCRX) Will Announce Quarterly Sales of $177.98 Million

Wall Street brokerages expect Pacira BioSciences, Inc. (NASDAQ:PCRXGet Rating) to post sales of $177.98 million for the current fiscal quarter, Zacks reports. Six analysts have issued estimates for Pacira BioSciences’ earnings, with the lowest sales estimate coming in at $169.92 million and the highest estimate coming in at $185.50 million. Pacira BioSciences reported sales of $135.59 million in the same quarter last year, which indicates a positive year-over-year growth rate of 31.3%. The business is scheduled to announce its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that Pacira BioSciences will report full year sales of $724.98 million for the current year, with estimates ranging from $705.19 million to $746.47 million. For the next financial year, analysts anticipate that the company will report sales of $856.05 million, with estimates ranging from $813.34 million to $951.32 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that follow Pacira BioSciences.

Pacira BioSciences (NASDAQ:PCRXGet Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported $0.64 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.19). Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The company had revenue of $157.99 million for the quarter, compared to analysts’ expectations of $155.08 million. During the same period in the prior year, the business earned $0.37 EPS. The business’s quarterly revenue was up 32.7% compared to the same quarter last year.

A number of equities research analysts have weighed in on the company. Northland Securities lifted their price objective on Pacira BioSciences from $61.00 to $67.00 in a report on Tuesday, March 1st. Wedbush reaffirmed a “buy” rating and issued a $94.00 price objective (down previously from $97.00) on shares of Pacira BioSciences in a report on Saturday, February 26th. HC Wainwright lifted their price objective on Pacira BioSciences from $86.00 to $90.00 and gave the company a “buy” rating in a report on Friday, February 25th. StockNews.com assumed coverage on Pacira BioSciences in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Finally, TheStreet lowered Pacira BioSciences from a “b-” rating to a “c” rating in a report on Thursday, February 24th. Three investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Pacira BioSciences has a consensus rating of “Buy” and an average target price of $80.63.

In other Pacira BioSciences news, insider Anthony Molloy sold 22,500 shares of the business’s stock in a transaction on Wednesday, April 6th. The stock was sold at an average price of $76.42, for a total value of $1,719,450.00. Following the completion of the transaction, the insider now directly owns 17,550 shares in the company, valued at approximately $1,341,171. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gary W. Pace sold 1,359 shares of the business’s stock in a transaction on Tuesday, March 1st. The shares were sold at an average price of $67.75, for a total value of $92,072.25. The disclosure for this sale can be found here. Insiders have sold a total of 69,607 shares of company stock valued at $5,092,865 over the last 90 days. Insiders own 5.20% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. UMB Bank N A MO acquired a new position in Pacira BioSciences in the 4th quarter valued at $25,000. First Horizon Advisors Inc. raised its holdings in Pacira BioSciences by 143.6% in the 4th quarter. First Horizon Advisors Inc. now owns 436 shares of the company’s stock valued at $26,000 after acquiring an additional 257 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Pacira BioSciences during the 1st quarter valued at $38,000. First Quadrant L P CA purchased a new stake in shares of Pacira BioSciences during the 4th quarter valued at $39,000. Finally, Catalyst Capital Advisors LLC purchased a new stake in shares of Pacira BioSciences during the 1st quarter valued at $42,000.

NASDAQ PCRX opened at $63.59 on Friday. Pacira BioSciences has a 52-week low of $45.05 and a 52-week high of $82.16. The business’s 50-day moving average price is $71.88 and its 200 day moving average price is $64.90. The firm has a market cap of $2.89 billion, a P/E ratio of 75.70 and a beta of 0.88. The company has a quick ratio of 1.85, a current ratio of 2.19 and a debt-to-equity ratio of 1.03.

About Pacira BioSciences (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

Featured Articles

Get a free copy of the Zacks research report on Pacira BioSciences (PCRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.